Search | Clinical Trials Finder

Conditions: Contrast Enhancement in Magnetic Resonance Imaging, Children
Interventions: Gadoquatrane (BAY1747846); Drug
Lead sponsor: Bayer; Industry
Eligibility: 0 Years to 17 Years
Enrollment: 105 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 3
States / cities: Indian Wells, California • Kansas City, Missouri • Charleston, South Carolina

Conditions: Knee Osteoarthritis
Interventions: lorecivivint; Drug
Lead sponsor: Biosplice Therapeutics, Inc.; Industry
Eligibility: 40 Years to 80 Years
Enrollment: 13 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 1
States / cities: San Francisco, California

Conditions: COVID Long-Haul
Interventions: [11C]CPPC Injection; Drug
Lead sponsor: Johns Hopkins University; Other
Eligibility: 18 Years and older
Enrollment: 6 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2026
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Brain Tumor
Interventions: ExAblate transcranial system; Device
Lead sponsor: InSightec; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2026
U.S. locations: 2
States / cities: Boston, Massachusetts • Seattle, Washington

Conditions: Parkinson's Disease
Interventions: VY-AADC01; Biological
Lead sponsor: Neurocrine Biosciences; Industry
Eligibility: 40 Years to 70 Years
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2020
U.S. locations: 2
States / cities: San Francisco, California • Pittsburgh, Pennsylvania

Conditions: Stroke
Interventions: piclozotan low dose, placebo, piclozotan high dose; Drug
Lead sponsor: Daiichi Sankyo; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 43 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2007
U.S. locations: 25
States / cities: Los Angeles, California • San Francisco, California • Hartford, Connecticut + 22 more

Conditions: Chronic Heart Failure (CHF)
Interventions: LCZ696, Valsartan, Placebo of LCZ696, Placebo of Valsartan; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 60 Years and older
Enrollment: 592 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2022
U.S. locations: 52
States / cities: Andalusia, Alabama • Glendale, Arizona • Mesa, Arizona + 45 more

Conditions: Pulmonary Hypertension, Cardiac MRI <40
Interventions: Carvedilol; Drug
Lead sponsor: University of Minnesota; Other
Eligibility: 18 Years to 99 Years
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Non-Transfusion Dependent Beta-Thalassemia (NTDT)
Interventions: REGN7999, Placebo; Drug
Lead sponsor: Regeneron Pharmaceuticals; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 19 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 1
States / cities: New York, New York

Conditions: Metabolic Dysfunction-Associated Steatohepatitis (MASH), Metabolic Dysfunction-associated Steatotic Liver Disease (MASLD)
Interventions: LY3849891, Placebo; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 115 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2026
U.S. locations: 13
States / cities: Chandler, Arizona • Orange, California • Rialto, California + 8 more

Conditions: Prostate Cancer
Interventions: MRI; Device
Lead sponsor: Stratagen Bio, Inc.; Industry
Eligibility: 40 Years to 90 Years · Male only
Enrollment: 75 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 2
States / cities: Rochester, New York • Richmond, Virginia

Conditions: Malignant Solid Tumor, Lymphomas
Interventions: RRx-001; Drug
Lead sponsor: EpicentRx, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 26 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2015
U.S. locations: 2
States / cities: La Jolla, California • Nashville, Tennessee

Conditions: Prostate Cancer
Interventions: MR-Guided Transurethral US Ablation of Prostate Tissue; Device
Lead sponsor: Profound Medical Inc.; Other
Eligibility: 65 Years to 75 Years · Male only
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2019
U.S. locations: 1
States / cities: Royal Oak, Michigan

Conditions: Malignant Glioma, Glioblastoma Multiforme, GBM, Astrocytoma, Oligodendroglioma
Interventions: TM-601; Drug
Lead sponsor: TransMolecular; Industry
Eligibility: 18 Years and older
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2010
U.S. locations: 7
States / cities: Birmingham, Alabama • Los Angeles, California • Chicago, Illinois + 4 more

Conditions: Arrhythmias, Cardiac
Interventions: MRI; Radiation
Lead sponsor: Banner Health; Other
Eligibility: 18 Years to 85 Years
Enrollment: 1,500 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2021
U.S. locations: 1
States / cities: Phoenix, Arizona

Conditions: Breast Cancer
Interventions: Gadobutrol (Gadavist, Gadovist, BAY86-4875); Drug
Lead sponsor: Bayer; Industry
Eligibility: 18 Years and older
Enrollment: 460 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 9
States / cities: Tucson, Arizona • Oakland, California • Englewood, Colorado + 6 more

Conditions: MRI
Interventions: MRI; Diagnostic Test
Lead sponsor: Oregon Health and Science University; Other
Eligibility: 9 Years to 99 Years
Enrollment: 10,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2030
U.S. locations: 2
States / cities: Portland, Oregon

Conditions: Magnetic Resonance Imaging
Interventions: Gadoxetate disodium (Eovist/Primovist, BAY86-4873); Drug
Lead sponsor: Bayer; Industry
Eligibility: Up to 2 Months
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015
U.S. locations: 9
States / cities: Los Angeles, California • Palo Alto, California • Washington D.C., District of Columbia + 6 more

Conditions: Safety of the ProMRI Pacemaker System Under Specific MRI Conditions
Interventions: Patients with a ProMRI Pacemaker System, Magnetic Resonance Imaging (MRI) scan; Device · Other
Lead sponsor: Biotronik, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 229 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 25
States / cities: Scottsdale, Arizona • Concord, California • Newport Beach, California + 22 more

Conditions: PAH
Interventions: 75mg CXA-10, 150mg CXA-10, Placebo; Drug · Other
Lead sponsor: Complexa, Inc.; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 69 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 40
States / cities: Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 34 more

Conditions: Movement Disorders, Parkinson Disease, Essential Tremor, Tremor, Dystonia
Interventions: Infinity DBS System with MR Conditional labelling; Device
Lead sponsor: Abbott Medical Devices; Industry
Eligibility: Not listed
Enrollment: 74 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 9
States / cities: Tucson, Arizona • Aurora, Colorado • Littleton, Colorado + 6 more

Conditions: Relapsing Multiple Sclerosis
Interventions: Remibrutinib oral treatment, Ocrelizumab; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 40 Years to 70 Years
Enrollment: 400 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2031
U.S. locations: 44
States / cities: Scottsdale, Arizona • Irvine, California • Washington D.C., District of Columbia + 39 more

Conditions: Contrast Enhancement in Magnetic Resonance Imaging, Non-central Nervous System Pathology
Interventions: Gadoquatrane (BAY1747846), Gadobutrol, Gadoterate meglumine, Gadoteridol; Drug
Lead sponsor: Bayer; Industry
Eligibility: 18 Years and older
Enrollment: 410 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 9
States / cities: Birmingham, Alabama • Indian Wells, California • Orange, California + 6 more

Conditions: Safety of a Customized NICU MRI System
Interventions: GE OPTIMA MR430s with HDX/GE Electronics; Device
Lead sponsor: Children's Hospital Medical Center, Cincinnati; Other
Eligibility: Not listed
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012
U.S. locations: 1
States / cities: Cincinnati, Ohio

Search by objective public record fields.

A Study to Learn How Gadoquatrane Moves Into, Through, and Out of the Body and How Safe it is in Children (From Birth to <18 Years), Who Will Undergo a Contrast Enhanced MRI (Quanti Pediatric)

MRI Study to Evaluate the Safety and Efficacy of SM04690 for Knee Osteoarthritis

Long COVID-19 [11C]CPPC Study

MRI-Guided Focused Ultrasound Feasibility Study for Brain Tumors

Safety Study of AADC Gene Therapy (VY-AADC01) for Parkinson's Disease

Efficacy of SUN N4057 in Subjects With Acute Ischemic Stroke and Measurable Penumbra on Magnetic Resonance Imaging (MRI)

Efficacy and Safety of LCZ696 Compared to Valsartan on Cognitive Function in Patients With Chronic Heart Failure and Preserved Ejection Fraction

Carvedilol PAH A Pilot Study of Efficacy and Safety

A Study to Test the Safety, Tolerability, and Efficacy of an Antibody, REGN7999, Injected Under the Skin for the Treatment of Iron Overload in Adult Participants With Non-Transfusion Dependent β-thalassemia, Using MRI Scans to Measure Iron Levels in the Body

A Single-Ascending and Repeated Dose Study of LY3849891 in Participants With Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)

Stratagen Quantitative Prostate MRI Platform Pilot Study

Safety and Pharmacokinetic Study of RRx-001 in Cancer Subjects

Safety Study of MRI-guided Transurethral Ultrasound Ablation of Prostate Tissue to Treat Localized Prostate Cancer

Safety and Dose-Finding Study of TM-601 in Adults With Recurrent Malignant Glioma

Safety of Magnetic Resonance Imaging in Non-MRI Conditional Pacemakers and ICD Devices

Efficacy and Safety of Gadobutrol 1.0 Molar (Gadovist) for Breast Magnetic Resonance Imaging (MRI)

VAPORHCS/OHSU J: MRI and Devices

Magnetic Resonance Imaging of the Liver in Children 0-2 Months of Age With an Intravenous Injection of Eovist/Primovist Which is a Contrast Agent

ProMRI Study of the Entovis Pacemaker System

PRIMEx - A Study of 2 Doses of Oral CXA-10 in Pulmonary Arterial Hypertension (PAH)

A Post-Market Study Evaluating the Safety of Infinity DBS System With MR Conditional Labeling

Efficacy and Safety of Remibrutinib After Switching From Ocrelizumab in Participants Living With Relapsing Multiple Sclerosis.

A Study to Compare How Well Gadoquatrane Works and Its Safety With an Already Available Contrast Agent for MRI in People With Any Known or Suspected Problems of the Body (Except Brain or Spinal Cord-related Problems)

Pilot Study: Safety of a Customized MRI System for Neonatal Imaging